HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, Z. Articles by Marrone, B. L. Search for Related Content PubMed PubMed Citation Articles by Wang, Z. Articles by Marrone, B. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB GLUTAMIC ACID HYDROCHLORIDE

Differential Susceptibilities to Chronic Beryllium Disease Contributed by Different Glu⁶⁹ HLA-DPB1 and -DPA1 Alleles¹

Zaolin Wang^*, P. Scott White^*, Michelle Petrovic^*, Owatha L. Tatum^*, Lee S. Newman, Lisa A. Maier and Babetta L. Marrone^2,*

^* Los Alamos National Laboratory, Los Alamos, NM; and National Jewish Medical and Research Center and University of Colorado Health Sciences Center, Denver, CO

Chronic beryllium disease (CBD) is associated with the allelic substitution of a Glu⁶⁹ in the HLA-DPB1 gene. Although up to 97% of CBD patients may have the Glu⁶⁹ marker, about 30–45% of beryllium-exposed, unaffected individuals carry the same marker. Because CBD occurs in only 1–6% of exposed workers, the presence of Glu⁶⁹ does not appear to be the sole genetic factor underlying the disease development. Using two rounds of direct automated DNA sequencing to precisely assign HLA-DPB1 haplotypes, we have discovered highly significant Glu⁶⁹-containing allele frequency differences between the CBD patients and a beryllium-exposed, nondiseased control group. Individuals with DPB1 Glu⁶⁹ in both alleles were almost exclusively found in the CBD group (6/20) vs the control group (1/75). Whereas most Glu⁶⁹ carriers from the control group had a DPB1 allele *0201 (68%), most Glu⁶⁹ carriers from the CBD group had a non-*0201 DPB1 Glu⁶⁹-carrying allele (84%). The DPB1 allele *0201 was almost exclusively (29/30) associated with DPA1 *01 alleles, while the non-*0201 Glu⁶⁹-containing DPB1 alleles were closely associated with DPA1 *02 alleles (26/29). Relatively rare Glu⁶⁹-containing alleles *1701, *0901, and *1001 had extremely high frequencies in the CBD group (50%), as compared with the control group (6.7%). Therefore, the most common Glu⁶⁹-containing DPB1 allele, *0201, does not seem to be a major disease allele. The results suggest that it is not the mere presence of Glu⁶⁹, per se, but specific Glu⁶⁹-containing alleles and their copy number (homozygous or heterozygous) that confer the greatest susceptibility to CBD in exposed individuals.

This article has been cited by other articles:

				D C Christiani, A J Mehta, and C-L Yu Genetic susceptibility to occupational exposures Occup. Environ. Med., June 1, 2008; 65(6): 430 - 436. [Abstract] [Full Text] [PDF]

				A. P. Fontenot, T. S. Keizer, M. McCleskey, D. G. Mack, R. Meza-Romero, J. Huan, D. M. Edwards, Y. K. Chou, A. A. Vandenbark, B. Scott, et al. Recombinant HLA-DP2 Binds Beryllium and Tolerizes Beryllium-Specific Pathogenic CD4+ T Cells J. Immunol., September 15, 2006; 177(6): 3874 - 3883. [Abstract] [Full Text] [PDF]

				J. R. Bill, D. G. Mack, M. T. Falta, L. A. Maier, A. K. Sullivan, F. G. Joslin, A. K. Martin, B. M. Freed, B. L. Kotzin, and A. P. Fontenot Beryllium Presentation to CD4+ T Cells Is Dependent on a Single Amino Acid Residue of the MHC Class II {beta}-Chain J. Immunol., November 15, 2005; 175(10): 7029 - 7037. [Abstract] [Full Text] [PDF]

				R. T. Sawyer, C. E. Parsons, A. P. Fontenot, L. A. Maier, M. M. Gillespie, E. B. Gottschall, L. Silveira, and L. S. Newman Beryllium-Induced Tumor Necrosis Factor-{alpha} Production by CD4+ T Cells Is Mediated by HLA-DP Am. J. Respir. Cell Mol. Biol., July 1, 2004; 31(1): 122 - 130. [Abstract] [Full Text] [PDF]

				L. A. Maier, D. S. McGrath, H. Sato, P. Lympany, K. Welsh, R. du Bois, L. Silveira, A. P. Fontenot, R. T. Sawyer, E. Wilcox, et al. Influence of MHC CLASS II in Susceptibility to Beryllium Sensitization and Chronic Beryllium Disease J. Immunol., December 15, 2003; 171(12): 6910 - 6918. [Abstract] [Full Text] [PDF]

				K. Gamerdinger, C. Moulon, D. R. Karp, J. van Bergen, F. Koning, D. Wild, U. Pflugfelder, and H. U. Weltzien A New Type of Metal Recognition by Human T Cells: Contact Residues for Peptide-independent Bridging of T Cell Receptor and Major Histocompatibility Complex by Nickel J. Exp. Med., May 19, 2003; 197(10): 1345 - 1353. [Abstract] [Full Text] [PDF]

				M. C. Iannuzzi, M. J. Maliarik, L. M. Poisson, and B. A. Rybicki Sarcoidosis Susceptibility and Resistance HLA-DQB1 Alleles in African Americans Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1225 - 1231. [Abstract] [Full Text] [PDF]

				E. C. McCanlies, K. Kreiss, M. Andrew, and A. Weston HLA-DPB1 and Chronic Beryllium Disease: A HuGE Review Am. J. Epidemiol., March 1, 2003; 157(5): 388 - 398. [Abstract] [Full Text] [PDF]

				M. Amicosante, F. Berretta, A. Franchi, P. Rogliani, C. Dotti, M. Losi, R. Dweik, and C. Saltini HLA-DP-unrestricted TNF-{alpha} release in beryllium-stimulated peripheral blood mononuclear cells Eur. Respir. J., November 1, 2002; 20(5): 1174 - 1178. [Abstract] [Full Text] [PDF]

				G. Malcolm Taylor, S. Dearden, P. Ravetto, M. Ayres, P. Watson, A. Hussain, M. Greaves, F. Alexander, O. B. Eden, and UKCCS Investigators Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201 Hum. Mol. Genet., July 1, 2002; 11(14): 1585 - 1597. [Abstract] [Full Text] [PDF]

				A. P. Fontenot, L. A. Maier, S. J. Canavera, T. B. Hendry-Hofer, M. Boguniewicz, E. A. Barker, L. S. Newman, and B. L. Kotzin Beryllium Skin Patch Testing to Analyze T Cell Stimulation and Granulomatous Inflammation in the Lung J. Immunol., April 1, 2002; 168(7): 3627 - 3634. [Abstract] [Full Text] [PDF]

				M. D. ROSSMAN, J. STUBBS, C. W. LEE, E. ARGYRIS, E. MAGIRA, and D. MONOS Human Leukocyte Antigen Class II Amino Acid Epitopes . Susceptibility and Progression Markers for Beryllium Hypersensitivity Am. J. Respir. Crit. Care Med., March 15, 2002; 165(6): 788 - 794. [Abstract] [Full Text] [PDF]

				R. M. du Bois The Genetic Predisposition to Interstitial Lung Disease : Functional Relevance Chest, March 1, 2002; 121(2007): 14S - 20S. [Abstract] [Full Text] [PDF]

				C. Saltini, L. Richeldi, M. Losi, M. Amicosante, C. Voorter, E. van den Berg-Loonen, R.A. Dweik, H.P. Wiedemann, D.C. Deubner, and C. Tinelli Major histocompatibility locus genetic markers of beryllium sensitization and disease Eur. Respir. J., October 1, 2001; 18(4): 677 - 684. [Abstract] [Full Text] [PDF]

				L. A. MAIER, R. T. SAWYER, R. A. BAUER, L. A. KITTLE, P. LYMPANY, D. MCGRATH, R. DUBOIS, E. DANILOFF, C. S. ROSE, and L. S. NEWMAN High Beryllium-stimulated TNF-alpha Is Associated with the -308 TNF-alpha Promoter Polymorphism and with Clinical Severity in Chronic Beryllium Disease Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1192 - 1199. [Abstract] [Full Text] [PDF]

				B. Nemery, A. Bast, J. Behr, P.J.A. Borm, S.J. Bourke, Ph. Camus, P. De Vuyst, H.M. Jansen, V.L. Kinnula, D. Lison, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility Eur. Respir. J., July 1, 2001; 18(32_suppl): 30S - 42s. [Abstract] [Full Text] [PDF]

				G. Lombardi, C. Germain, J. Uren, M. T. Fiorillo, R. M. du Bois, W. Jones-Williams, C. Saltini, R. Sorrentino, and R. Lechler HLA-DP Allele-Specific T Cell Responses to Beryllium Account for DP-Associated Susceptibility to Chronic Beryllium Disease J. Immunol., March 1, 2001; 166(5): 3549 - 3555. [Abstract] [Full Text] [PDF]

				S. M. Tarlo, K. Rhee, E. Powell, E. Amer, L. Newman, G. Liss, and N. Jones Marked Tachypnea in Siblings With Chronic Beryllium Disease due to Copper-Beryllium Alloy Chest, February 1, 2001; 119(2): 647 - 650. [Abstract] [Full Text] [PDF]

				A. P. Fontenot, M. Torres, W. H. Marshall, L. S. Newman, and B. L. Kotzin Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease PNAS, October 23, 2000; (2000) 220430797. [Abstract] [Full Text]

				A. P. Fontenot, M. Torres, W. H. Marshall, L. S. Newman, and B. L. Kotzin Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease PNAS, November 7, 2000; 97(23): 12717 - 12722. [Abstract] [Full Text] [PDF]